Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Everolimus (Afinitor) tablets
DRUG
2 trials
Sponsors
Exelixis
, Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions
Colorectal Cancer
Renal Cell Carcinoma
Phase 1
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)
Not yet recruiting
NCT07435584
Second Affiliated Hospital, School of Medicine, Zhejiang University
Colorectal Cancer
Start: 2026-03-01
End: 2028-12-31
Target: 38
Updated: 2026-02-27
Phase 3
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Completed
NCT01865747
Exelixis
Renal Cell Carcinoma
Start: 2013-06-30
End: 2021-01-15
Updated: 2021-04-27
Related Papers
Abstract 6370: Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents
Cancer Research
2025-04-21
RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment
Radiology Imaging Cancer
2023-09-01
7 citations
Authors’ reply to Bhattacharya
Cancer Research Statistics and Treatment
2023-04-01
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
2023-01-03
5 citations
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
Clinical Cancer Research
2021-12-16
22 citations
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
2021-11-04
1 citations
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
2021-08-07
16 citations
Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients
International Journal of Urology
2020-08-12
27 citations
A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.
Journal of Clinical Oncology
2020-05-20
6 citations
Metastasiertes Nierenzellkarzinom: Ist das Alter therapierelevant?
Kompass Onkologie
2020-01-01
Metastasiertes Nierenzellkarzinom: Cabozantinib als Behandlungsoption für ältere Patienten
Kompass Onkologie
2020-01-01
Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
Kidney Cancer
2019-12-28
3 citations
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
European Journal of Cancer
2019-12-27
26 citations
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Clinical Cancer Research
2019-08-01
54 citations
Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
Journal of Clinical Oncology
2019-03-01
4 citations
Unexpected Success for a TKI in Activating Anticancer Innate Immunity
Oncology Times
2018-10-30
Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England.
2018-04-23
13 citations
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
2018-03-26
43 citations
Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).
Journal of Clinical Oncology
2018-02-20
1 citations
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
Journal of Clinical Oncology
2018-01-29
55 citations
13 more papers not shown